Identify all immunogenic areas of a target compound for improved immunogenicity risk assessment
Optimize drug design and modulate sequences at an early stage
Get recommendations from experts with over 10+ years of experience
Immunogenicity risk assessment is the evaluation of the ability of a (bio)therapeutic to induce an adverse immunogenic response in a patient, predicts the long-term efficacy of the biotherapeutic and identifies potential safety concerns for unwanted immunogenicity.
Immunopeptidomics or MAPPS (MHC associated peptide proteomics) involves the identification and characterization of antigen fragments (immunopeptides) loaded intracellularly on major histocompatibility complex (MHC) molecules and presented extracellularly to T cells.
MAPPS is the most accurate and reliable testing method to assess which regions of a biotherapeutic might be immunogenic as they can be presented by MHC complexes and may trigger a T cell response.
Our advanced immunopeptidomics platform provides a more thorough analysis of immunogenic areas of candidate biotherapeutics and leads to more accurate results. ImmuneSpec's data will facilitate drug design optimization, enable more accurate predictions for adverse events during clinical stages, and provides support data for regulatory approval on safety and efficacy.
Institute of Tropical Medicine Antwerp
Experience the benefits of our high-quality products and exceptional service.